EagleClaw Capital Management’s Eli Lilly LLY Stock Holding History

EagleClaw Capital Management’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.65M	Buy	1,797 +27	+2%	+$27.4K	0.23%	79
2025 Q4	$1.9M	Sell	1,770 -50	-3%	-$47.8K	0.28%	79
2025 Q3	$1.39M	Buy	1,820 +105	+6%	+$78.1K	0.19%	86
2025 Q2	$1.34M	Buy	1,715 +7	+0.4%	+$5.44K	0.2%	86
2025 Q1	$1.41M	Sell	1,708 -10	-0.6%	-$8.32K	0.22%	83
2024 Q4	$1.33M	Hold	1,718	–	–	0.21%	83
2024 Q3	$1.52M	Sell	1,718 -7	-0.4%	-$6.29K	0.25%	79
2024 Q2	$1.56M	Hold	1,725	–	–	0.28%	80
2024 Q1	$1.34M	Sell	1,725 -60	-3%	-$42.7K	0.24%	82
2023 Q4	$1.04M	Hold	1,785	–	–	0.22%	83
2023 Q3	$959K	Hold	1,785	–	–	0.22%	81
2023 Q2	$837K	Sell	1,785 -25	-1%	-$10.5K	0.19%	88
2023 Q1	$622K	Buy	1,810 +185	+11%	+$62.4K	0.15%	94
2022 Q4	$594K	Buy	1,625 +975	+150%	+$346K	0.14%	93
2022 Q3	$210K	Hold	650	–	–	0.06%	123
2022 Q2	$211K	Sell	650 -50	-7%	-$15K	0.06%	123
2022 Q1	$200K	Sell	700 -50	-7%	-$12.9K	0.05%	134
2021 Q4	$207K	Buy	+750	New	+$190K	0.05%	138

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EagleClaw Capital Management's LLY Position: Q1 2026 in Review

EagleClaw Capital Management increased its Eli Lilly (LLY) stake by 1.5% in Q1 2026, buying an estimated $27.4K and bringing the position to 1,797 shares worth $1.65M. The position accounts for 0.23% of the portfolio, ranked #79.

EagleClaw Capital Management first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.9M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

EagleClaw Capital Management held 1,797 shares of Eli Lilly worth $1.65M as of Q1 2026.
EagleClaw Capital Management bought 27 Eli Lilly shares in Q1 2026, an estimated $27.4K.
Eli Lilly made up 0.23% of EagleClaw Capital Management's portfolio in Q1 2026, its #79 holding.
EagleClaw Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
EagleClaw Capital Management's Eli Lilly position peaked at $1.9M in Q4 2025.
4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.